CA2810292A1 - Ligand pour recepteur fprl2 couple aux proteines g et leur utilisation - Google Patents

Ligand pour recepteur fprl2 couple aux proteines g et leur utilisation Download PDF

Info

Publication number
CA2810292A1
CA2810292A1 CA2810292A CA2810292A CA2810292A1 CA 2810292 A1 CA2810292 A1 CA 2810292A1 CA 2810292 A CA2810292 A CA 2810292A CA 2810292 A CA2810292 A CA 2810292A CA 2810292 A1 CA2810292 A1 CA 2810292A1
Authority
CA
Canada
Prior art keywords
polypeptide
fprl2
activity
hbp
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2810292A
Other languages
English (en)
Other versions
CA2810292C (fr
Inventor
Isabelle Migeotte
Marc Parmentier
David Communi
Maryse Brait
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ogeda SA
Original Assignee
Euroscreen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euroscreen SA filed Critical Euroscreen SA
Publication of CA2810292A1 publication Critical patent/CA2810292A1/fr
Application granted granted Critical
Publication of CA2810292C publication Critical patent/CA2810292C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention porte sur des méthodes, des agents réactifs et des trousses de détection de l'activité polypeptide d'un récepteur de peptide formyle comme le FPRL2 dans un échantillon et l'identification des agents qui modulent l'activité polypeptidique. Elle porte également sur des anticorps élevés contre le FPRL2. Elle porte aussi sur des substances destinées à prévenir, traiter ou diminuer les maladies et les désordres caractérisés par la dysrégulation du signalement de polypeptide FPRL2.
CA2810292A 2004-05-14 2005-05-04 Ligand pour recepteur fprl2 couple aux proteines g et leur utilisation Active CA2810292C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP04447122 2004-05-14
EP04447122.5 2004-05-14
EP04447231.4 2004-10-18
EP04447231 2004-10-18
CA2504920A CA2504920C (fr) 2004-05-14 2005-05-04 Ligand pour recepteur fprl2 couple aux proteines g et leur utilisation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2504920A Division CA2504920C (fr) 2004-05-14 2005-05-04 Ligand pour recepteur fprl2 couple aux proteines g et leur utilisation

Publications (2)

Publication Number Publication Date
CA2810292A1 true CA2810292A1 (fr) 2005-11-14
CA2810292C CA2810292C (fr) 2015-09-29

Family

ID=34982585

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2504920A Active CA2504920C (fr) 2004-05-14 2005-05-04 Ligand pour recepteur fprl2 couple aux proteines g et leur utilisation
CA2810292A Active CA2810292C (fr) 2004-05-14 2005-05-04 Ligand pour recepteur fprl2 couple aux proteines g et leur utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2504920A Active CA2504920C (fr) 2004-05-14 2005-05-04 Ligand pour recepteur fprl2 couple aux proteines g et leur utilisation

Country Status (7)

Country Link
US (3) US7582416B2 (fr)
EP (2) EP1607745B1 (fr)
JP (2) JP4694887B2 (fr)
AT (2) ATE496304T1 (fr)
CA (2) CA2504920C (fr)
DE (2) DE602005026072D1 (fr)
DK (2) DK2020604T3 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4486256B2 (ja) * 1998-10-22 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション 副甲状腺ホルモン（ＰＴＨ）および副甲状腺ホルモン関連ペプチド（ＰＴＨｒＰ）の生物活性ペプチドおよびペプチド誘導体
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
WO2003009804A2 (fr) * 2001-07-23 2003-02-06 The General Hospital Corporation Analogues d'hormone parathyroide (pth) a contrainte conformationnelle
US7795220B2 (en) * 2003-03-19 2010-09-14 The General Hospital Corporation Conformationally constrained parathyroid hormones with alpha-helix stabilizers
EP1653985A4 (fr) 2003-07-17 2009-08-05 Gen Hospital Corp Analogues d'hormone parathyroide (pth) a conformation contrainte
CA2504920C (fr) * 2004-05-14 2014-04-01 Euroscreen S.A. Ligand pour recepteur fprl2 couple aux proteines g et leur utilisation
JP2009545320A (ja) * 2006-08-04 2009-12-24 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン（ｐｔｈ）のポリペプチド誘導体
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US20090042869A1 (en) * 2007-06-20 2009-02-12 University Of Utah Research Foundation SIGNAL-DEPENDENT SPLICING OF TISSUE FACTOR PRE-mRNA IN PLATELET CELLS
MX353986B (es) 2007-08-01 2017-11-06 Massachusetts Gen Hospital Metodos de analisis y seleccion usando receptores acoplados a proteina g y composiciones relacionadas.
US8652785B2 (en) * 2008-12-04 2014-02-18 Sanofi Method of screening a modulator of endothelial NO synthase comprising the use of heme binding protein 1
DK2432760T3 (da) 2009-05-18 2013-09-08 Actelion Pharmaceuticals Ltd Brokoblede spiro [2.4]-heptanderivater som alx-receptor og/eller fprl2-agonister
WO2011073918A2 (fr) 2009-12-16 2011-06-23 Actelion Pharmaceuticals Ltd Peptides au titre de modulateurs de fprl1 et/ou de fprl2
MX358161B (es) 2010-05-13 2018-08-06 The General Hospital Corp Star Analogos de hormona paratiroidea y usos para los mismos.
US11536716B2 (en) 2015-06-25 2022-12-27 Hoffmann-La Roche Inc. Cell based assay for determining antibody or ligand binding and function

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003345A1 (fr) 1988-11-18 1990-05-18 Joel F. Habener Proteine de liaison de stimulateur de transcription reagissant au camp
WO1993006213A1 (fr) 1991-09-23 1993-04-01 Medical Research Council Production d'anticorps chimeriques - une approche combinatoire
CA2115811A1 (fr) 1993-02-17 1994-08-18 Claus Krebber Methode de selection in vivo de proteines fixatrices de ligands
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
US7119190B2 (en) * 1997-04-14 2006-10-10 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human G protein-coupled receptors
WO2000002045A2 (fr) 1998-07-06 2000-01-13 Euroscreen S.A. Diagnostic a haut rendement et/ou procede de dosage d'un agoniste et/ou antagoniste d'un recepteur a couplage calcium
WO2001019860A2 (fr) * 1999-09-15 2001-03-22 Incyte Genomics, Inc. Proteines associees a la differenciation cellulaire
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP4184875B2 (ja) * 2002-06-14 2008-11-19 武田薬品工業株式会社 新規スクリーニング方法
CA2504920C (fr) * 2004-05-14 2014-04-01 Euroscreen S.A. Ligand pour recepteur fprl2 couple aux proteines g et leur utilisation

Also Published As

Publication number Publication date
DK1607745T3 (da) 2010-06-14
CA2810292C (fr) 2015-09-29
US20100009406A1 (en) 2010-01-14
US20060078559A1 (en) 2006-04-13
US7659251B2 (en) 2010-02-09
EP1607745A3 (fr) 2006-07-26
JP2011078437A (ja) 2011-04-21
EP2020604B1 (fr) 2011-01-19
JP4694887B2 (ja) 2011-06-08
ATE496304T1 (de) 2011-02-15
ATE459004T1 (de) 2010-03-15
EP1607745B1 (fr) 2010-02-24
JP2006025787A (ja) 2006-02-02
US7582416B2 (en) 2009-09-01
DE602005026072D1 (de) 2011-03-03
EP2020604A1 (fr) 2009-02-04
CA2504920A1 (fr) 2005-11-14
EP1607745A2 (fr) 2005-12-21
US20090053739A1 (en) 2009-02-26
US7842795B2 (en) 2010-11-30
DE602005019495D1 (de) 2010-04-08
JP5314061B2 (ja) 2013-10-16
CA2504920C (fr) 2014-04-01
DK2020604T3 (da) 2011-05-16

Similar Documents

Publication Publication Date Title
CA2810292C (fr) Ligand pour recepteur fprl2 couple aux proteines g et leur utilisation
US7582734B2 (en) Functional antibodies that specifically bind to the Chemerin receptor
US7332291B2 (en) Methods of identifying modulators of ligand binding to ChemerinR polypeptides
US7422846B2 (en) Natural ligand for orphan G protein coupled receptor GPR86 and methods of use
CA2589393C (fr) Ligand pour recepteur gpr72 lie a la proteine-g et utilisations connexes
US20030232756A1 (en) Ligands for G protein coupled receptor GPR7 and GPR8 and uses thereof
US20070213510A1 (en) Compositions and methods comprising a ligand of ChemerinR
US8030453B2 (en) Methods of making an antibody that binds a chemerin polypeptide
US7470772B2 (en) Antibody that specifically binds to Chemerin receptor ligand precursor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130319